Phase 2 study comparing the efficacy between afatinib & osimertinib based on immunological biomarker in EGFR-mutant NSCLC

被引：0
|
作者：
Morikawa, Kei [1 ]
Tanaka, Hisashi [2 ]
Takata, Saori [3 ]
Watanabe, Satoshi [4 ]
Kishi, Kazuma [5 ]
Soejima, Kenzo [6 ]
Kaira, Kyoichi [7 ]
Kagamu, Hiroshi [7 ]
Yoshimura, Kenichi [8 ]
Matsutani, Noriyuki [9 ]
Seki, Nobuhiko [10 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Kanagawa, Japan
[2] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan
[3] Kyorin Univ, Dept Resp Med, Sch Med, Mitaka, Tokyo, Japan
[4] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan
[5] Toho Univ, Omori Med Ctr, Dept Resp Med, Tokyo, Japan
[6] Keio Univ Hosp, Clin & Translat Res Ctr, Tokyo, Japan
[7] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Moroyama, Saitama, Japan
[8] Hiroshima Univ Hosp, Med Ctr Translat & Clin Res, Hiroshima, Japan
[9] Teikyo Univ Hosp, Dept Surg, Mizonokuchi, Japan
[10] Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P68-3
引用
收藏
页码：S538 / S538
页数：1
相关论文
共 50 条
  • [21] Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Shipitofsky, N.
    Vigliotti, M.
    Goldberg, T.
    Li, J.
    Mcgill, J.
    Zhang, H.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S801 - S801
  • [22] Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Vigliotti, M.
    Shipitofsky, N.
    Li, J.
    Mcgill, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2289 - S2290
  • [23] Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study
    Meng, X.
    Kong, L.
    Zhao, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S581 - S581
  • [24] Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
    Riess, Jonathan W.
    Krailo, Mark D.
    Padda, Sukhmani Kaur
    Groshen, Susan G.
    Wakelee, Heather A.
    Reckamp, Karen L.
    Koczywas, Marianna
    Piotrowska, Zofia
    Steuer, Conor Ernst
    Kim, Chul
    Paweletz, Cloud P.
    Sholl, Lynette M.
    Heavey, Grace
    Kolesar, Jill
    Moscow, Jeffrey
    Janne, Pasi A.
    Lara, Primo
    Newman, Edward M.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
    Planchard, D.
    Janne, P. A.
    Yu, H. A.
    Moro-Sibilot, D.
    Goldberg, T.
    Gu, X.
    Li, J.
    McGill, J.
    Yu, C.
    Slosberg, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study
    Hata, A.
    Takase, N.
    Sumi, T.
    Yoshioka, H.
    Fujisaka, Y.
    Ota, T.
    Osugi, J.
    Mitsui, M.
    Morita, R.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1659 - S1659
  • [27] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [28] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [29] Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
    Leighl, N. B.
    Shu, C. A.
    Minchom, A.
    Felip, E.
    Cousin, S.
    Cho, B. C.
    Park, K.
    Han, J-Y.
    Boyer, M.
    Lee, C. K.
    Moreno Garcia, V.
    Tomasini, P.
    Viteri, S.
    Xie, J.
    Mertz, J.
    Artis, E.
    Schnepp, R. W.
    Knoblauch, R. E.
    Thayu, M.
    Trigo Perez, J. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S951 - S952
  • [30] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
12345